NKILA

Summary

NKILA (NF-kappaB interacting lncRNA, HGNC:51599) is a long non-coding RNA gene on chromosome 20q13.31.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:51599
Approved symbol	NKILA
Name	NF-kappaB interacting lncRNA
Location	20q13.31
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000278709
Ensembl biotype	lncRNA
OMIM	621181
Entrez	105416157
RNAcentral	URS00008120E1 — lncRNA, 2615 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 lncRNA

ENST00000613231, ENST00000614771

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000613231 — 2 exons

Exon	Start	End
ENSE00003742452	57710183	57710614
ENSE00003744134	57711262	57711366

Expression profiles

Bgee: expression breadth ubiquitous, 152 present calls, max score 85.56.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9064 / max 59.0675, expressed in 769 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185487	2.9064	769

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.56	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.76	silver quality
bone marrow cell	CL:0002092	72.17	gold quality
colonic epithelium	UBERON:0000397	69.65	silver quality
islet of Langerhans	UBERON:0000006	69.33	gold quality
hindlimb stylopod muscle	UBERON:0004252	69.26	gold quality
prostate gland	UBERON:0002367	66.79	gold quality
ventricular zone	UBERON:0003053	64.72	gold quality
ascending aorta	UBERON:0001496	63.39	gold quality
ganglionic eminence	UBERON:0004023	63.34	gold quality
thoracic aorta	UBERON:0001515	63.25	gold quality
descending thoracic aorta	UBERON:0002345	62.79	gold quality
cortical plate	UBERON:0005343	62.16	gold quality
tendon of biceps brachii	UBERON:0008188	61.43	gold quality
aorta	UBERON:0000947	61.40	gold quality
smooth muscle tissue	UBERON:0001135	61.20	gold quality
heart left ventricle	UBERON:0002084	61.17	gold quality
pancreas	UBERON:0001264	60.68	gold quality
right atrium auricular region	UBERON:0006631	60.68	gold quality
cardiac ventricle	UBERON:0002082	60.52	gold quality
popliteal artery	UBERON:0002250	60.22	gold quality
tibial artery	UBERON:0007610	60.20	gold quality
cardiac atrium	UBERON:0002081	60.15	gold quality
heart	UBERON:0000948	59.98	gold quality
muscle of leg	UBERON:0001383	59.20	gold quality
left coronary artery	UBERON:0001626	59.05	gold quality
tendon	UBERON:0000043	58.68	silver quality
prefrontal cortex	UBERON:0000451	58.63	gold quality
apex of heart	UBERON:0002098	58.33	gold quality
gastrocnemius	UBERON:0001388	57.96	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.73

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 37)

• NKILA is a vital determinant of tongue squamous cell carcinoma cell migration and invasion; the NF-kappaB signaling pathway mediates this effect (PMID:27613832)
• Study found that the expression of NKILA was downregulated in tumor tissues of non-small cell lung cancer (NSCLC), which improved the metastasis of NSCLC patients. In vitro studies further clarified that the expression of NKILA was regulated through classical TGF-beta signal pathway, which subsequently inhibited migration and invasion of NSCLC cells through interfering with NF-KB/Snail signal pathway in NSCLC cells. (PMID:28412955)
• NKILA could function as a tumor suppressor through inhibition of cell proliferation and migration in vitro and in vivo. Thus, NKILA exerts clinical significance and may serve as a prognostic marker and therapeutic target of Esophageal Squamous cell carcinoma. (PMID:29348395)
• Our research demonstrated that NKILA acts downstream of the TGF-beta signaling pathway and inhibits cell invasion and metastasis by inhibiting IkappaBalpha phosphorylation and NF-kappaB activation and, consequently, suppressing MMP14 expression. Moreover, NKILA expression levels are decreased in the advanced tumor tissues of patients with esophageal squamous cell carcinoma. (PMID:29379981)
• NF-kappaB binds to the promoter region of NKILA to activate its transcriptional activity, upregulated NKILA then inhibits IkappaB phosphorylation and NF-kappaB activation, thus forming a negative feedback loop to sensitize laryngeal cancer cell to X-ray radiation. (PMID:29573243)
• Low NKILA expression is associated with metastasis in breast cancer. (PMID:29761481)
• Hypoxia-induced NKILA expression negatively regulates NF-kappa B to promote retinal pigment epithelium cell death. (PMID:30144973)
• NKILA serves as an antioncogenic lncRNA in rectal cancer.NKILA expression was decreased in rectal cancer, and associated with clinical progression and prognosis. NKILA-inhibited rectal cancer cell proliferation, migration, and invasion via suppressing NF-kappaB signaling. (PMID:30171719)
• NKILA overexpression in tumor-specific cytotoxic T lymphocytes and TH1 cells correlated with their apoptosis and shorter survival in patients with breast and lung cancer (PMID:30224822)
• KLF4 can inversely attenuate NF-kappaB transcriptional activity via establishing a NF-kappaB/KLF4 positive feedback loop. (PMID:30419187)
• LncRNA NKILA Inhibits Retinoblastoma by Downregulating lncRNA XIST. (PMID:30995132)
• LncRNA NKILA inhibits invasion and migration of osteosarcoma cells via NF-kappaB/Snail signaling pathway. (PMID:31173281)
• Authors found that plasma lncRNA NKILA was expressed at higher levels in active ankylosing spondylitis patients than in healthy controls. (PMID:31173579)
• NF-kappaB/NKILA signaling modulates the anti-cancerous effects of EZH2 inhibition. (PMID:31282094)
• NKILA expression was identified to be decreased in nasopharyngeal carcinoma (NPC) tissues. Low NKILA expression was correlated with unfavorable clinicopathological features and predicted poor survival outcome in NPC patients. NKILA overexpression in high-metastatic-potential NPC cells repressed motile behavior and impaired the metastatic capacity in vitro and in vivo through the NF-kappaB pathway. (PMID:31430288)
• LncRNA NKILA integrates RXFP1/AKT and NF-kappaB signalling to regulate osteogenesis of mesenchymal stem cells. (PMID:31657882)
• Overexpression of NKILA could inhibit cell proliferation, migration and promote apoptosis of breast cancer cells. It could also inhibit cell proliferation, migration and angiogenesis of HUVEC through inhibiting IL-6 secretion via NF-kappaB signaling pathway. (PMID:31862380)
• Expression analysis of inflammatory response-associated genes in coronary artery disease. (PMID:31913058)
• LncRNA NKILA inhibits the proliferation and promotes the apoptosis of CSCC cells by downregulating miRNA-21. (PMID:31950510)
• The reduced lncRNA NKILA inhibited proliferation and promoted apoptosis of chondrocytes via miR-145/SP1/NF-kappaB signaling in human osteoarthritis. (PMID:32016955)
• NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas. (PMID:32382013)
• NF-kappaB-Interacting Long Noncoding RNA Regulates HIV-1 Replication and Latency by Repressing NF-kappaB Signaling. (PMID:32581100)
• Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis. (PMID:32851072)
• Effects of lncRNA MALAT1 and lncRNA NKILA on proliferation, invasion and apoptosis of retinoblastoma. (PMID:32894536)
• Long Non-Coding RNA NKILA Reduces Oral Squamous Cell Carcinoma Development Through the NF-KappaB Signaling Pathway. (PMID:33143574)
• Long noncoding RNA NKILA transferred by astrocyte-derived extracellular vesicles protects against neuronal injury by upregulating NLRX1 through binding to mir-195 in traumatic brain injury. (PMID:33686956)
• Attenuated lncRNA NKILA Enhances the Secretory Function of Airway Epithelial Cells Stimulated by Mycoplasma pneumoniae via NF-kappaB. (PMID:33855076)
• LncRNA NKILA knockdown promotes cell viability and represses cell apoptosis, autophagy and inflammation in lipopolysaccharide-induced sepsis model by regulating miR-140-5p/CLDN2 axis. (PMID:33932903)
• Sequence-dependent recruitment of SRSF1 and SRSF7 to intronless lncRNA NKILA promotes nuclear export via the TREX/TAP pathway. (PMID:34096602)
• Long non-coding RNA NKILA regulates expression of HSP90alpha, NF-kappaB and beta-catenin proteins in the MCF-7 breast cancer cell line. (PMID:34125329)
• Epigenetic Silencing of Tumor Suppressor lncRNA NKILA: Implication on NF-kappaB Signaling in Non-Hodgkin’s Lymphoma. (PMID:35052468)
• m(5) C and m(6) A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR-582-3p-YAP1 axis. (PMID:35274813)
• LncRNA NKILA Exacerbates Alzheimer’s Disease Progression by Regulating the FOXA1-Mediated Transcription of TNFAIP1. (PMID:37217807)
• LncRNA NKILA inhibits HBV replication by repressing NF-kappaB signalling activation. (PMID:37832719)
• Expression profile of long-noncoding RNAs MIR31HG, NKILA, and PACER in systemic lupus erythematosus patients. (PMID:38395324)
• Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis. (PMID:38745302)
• Association between NKILA and some apoptotic gene expression in atherosclerosis. (PMID:39184397)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.